findmyKOL
Clinical trialNCT00004184CompletedPhase 1/PHASE2Interventional

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

SponsorUniversity of Alabama at BirminghamEnrollment50Melanoma (Skin)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have stage III or stage IV melanoma at high risk for recurrence following surgery to remove the tumor.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Donald M. Miller, MD, PhD

    James Graham Brown Cancer Center at University of Louisville

    Study Chair

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Alum adjuvantMonoclonal antibody 4B5 anti-idiotype vaccineSargramostim →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 1998
Primary completion
30 Jun 2001
Completion
30 Jun 2001
Last update posted
12 Apr 2013
Registered enrollment
50
Registry id
NCT00004184

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.